Matthew Mallory, MD
Radiation Oncology · Fayetteville, ARNPI 1194145532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations.
Across 59 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$99
- Regeneron Healthcare Solutions, Inc.$88
- Eisai Inc.$72
- Amgen$52
- Sanofi$46
- Merck$45
- plus $496 from 22 others
What the payments were for
- Food & beverage$898100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $99 |
| Regeneron Healthcare Solutions, Inc. | 6 | $88 |
| Eisai Inc. | 5 | $72 |
| Amgen | 3 | $52 |
| Sanofi | 2 | $46 |
| Merck | 3 | $45 |
| Sobi, Inc | 3 | $43 |
| Johnson & Johnson | 3 | $38 |
| Tersera Therapeutics LLC | 2 | $37 |
| Rigel Pharmaceuticals, Inc. | 3 | $36 |
| AVEO Pharmaceuticals, Inc. | 2 | $33 |
| Novocure Inc. | 1 | $33 |
| Taiho Oncology, Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 2 | $28 |
| G1 Therapeutics, Inc. | 2 | $26 |
| Heron Therapeutics, Inc. | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Genmab U.S., Inc. | 1 | $15 |
| Telix Pharmaceuticals | 1 | $15 |
| Pharmaessentia USA Corporation | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Servier Pharmaceuticals LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| CTI Biopharma Corp. | 1 | $13 |
| Exelixis Inc. | 1 | $13 |
| Bayer | 1 | $12 |
How this compares
$898 in reported general payments places this provider in the 55th percentile of 45 radiation oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 74 | $535 |
| Oxybutynin Chloride ErOxybutynin Chloride | 20 | $267 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Fayetteville
- Foster LasleyFayetteville$8K
- Chris McClintonFayetteville$4K
- Wesley GarnerFayetteville$3K
- Arnold SmithFayetteville$3K
- Hershel GarnerFayetteville$2K
- Joshua AndersonFayetteville$98
- Joseph RossFayetteville$61
- Scarlett Acklin-WehnertFayetteville$14
- Matthew McKeeverFort Smith$5K
- Fen XiaLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.